WANDERCRAFT SAS aus Paris auf der MEDICA 2018 in Düsseldorf -- COMPAMED Messe
Premium-Aussteller Hersteller


88, rue de Rivoli, 75004 Paris


MEDICA 2018 Hallenplan (Halle 4): Stand H22


MEDICA 2018 Geländeplan: Halle 4





Jean-Louis Constanza



Unser Angebot


  • 04  Physiotherapie / Orthopädietechnik
  • 04.12  Rehabilitationsgeräte, Rehabilitationssysteme

Rehabilitationsgeräte, Rehabilitationssysteme

Unsere Produkte

Produktkategorie: Rehabilitationsgeräte, Rehabilitationssysteme

Autonomous walk exoskeleton

Wandercraft's exo is the first autonomous walk exoskeleton. It is also the first to have the potential to restore outpatient autonomy. Delivering autonomous and realistic ambulation requires two complementary technologies: (1) dynamic robotics algorithms and mechatronics, that accommodate unbalanced situations during the stride and calculate trajectories and foot placement at each point of the gait cycle to re-create balance; (2) 12 actuated degrees of freedom, to allow physiological movements.  The 2018 Rehab Center version provides the following innovative features:

- Autonomous walk and sitting/standing manoeuvers, without crutches
- Getting rid of crutches and the related strain upon upper body, allowing for medical hypotheses on the impact of higher treatment repetition and intensity without upper limb damage or excessive energy consumption
- More realistic patient posture and gait, allowing for hypotheses on the impact of better leveraging neural plasticity
A strong emphasis has been put on tolerance of the exo by the patient, in order to allow repeated, frequent therapy sessions. In the first clinical trials, patients remained several hours in a row in the exo under medical supervision, with no significant fatigue nor skin lesions. Medical teams working with Wandercraft plan to leverage the exo’s unique self-balancing and gait realism to validate hypotheses on its potential to increase treatment efficacy in three areas:

- Rehabilitation, with hypotheses on factors such as: (1)more realistic gait; (2)increased doses allowed by the absence of strain on upper limbs and lower energy consumption; could enable more efficient and effective rehabilitation.
- Addressing associated diseases resulting from sedentary life in a wheelchair, with hypotheses on the impact of more realistic gait and potentially higher doses of treatment. Associated diseases may include conditions related to cardiovascular, joint restrictions, digestion and urinary, overweight and posture, possibly bone density and self-image.
The Rehab Center version is being industrialized, should be CE marked end-2018 as a Class IIa medical device and then commercialized in Europe. Functionalities:

- Allowing treatment sessions with autonomous standing up, keeping standing balance with intrinsic perturbations, walking, turning, sitting down
- Easy and safe patient transfer, donning and doffing
- Bio-compatible user interface and braces allowing for frequent rehab sessions
- Short training times for therapists and patients

Mehr Weniger

Über uns


Founded in 2012, Wandercraft develops the first robotic exoskeleton providing autonomous, crutch-less, and gradually realistic walk, for SCI, neuromuscular diseases, post-stroke hemiparesis, MS, CP, Parkinson and others. The first commercial Rehab Center version should be proposed to European Physical Medicine and Neurology hospitals and healthcare centers by the end of 2018. FDA approval process will start momentarily.

Wandercraft has developed the world’s first autonomous, self-stabilized dynamically walking exoskeleton. The exo offers disruptive perspectives, to be proven clinically, in rehabilitation, addressing associated diseases and restoring sufficient autonomy in daily life. Wandercraft leverages state of the art robotics and works with advanced medical teams to progress towards:

- More effective inpatient treatments and higher exercise doses in the same timeframe, with a potential to better leverage brain/neural plasticity where relevant, and to better address associated pathologies

- Significant improvement in outpatient quality of life and higher inclusion in patient communities

- Thanks to a unique synergy between restored autonomy and the impact of daily outpatient ambulation, pursuing a continuous treatment in rehabilitation and on associated pathologies, with a near-real time follow up by the patient’s medical environment

- Lower impact of associated diseases leading to lower health cost for mobility impaired persons

In a few years, a personal version will be issued to increase patient autonomy in their outpatient daily lives while pursuing treatment.

Development perspectives:

Rehab Center version:

CE marking and commercialization of the first autonomous exo for Rehabilitation and healthcare institutions, enabling medical teams to conduct more effective Inpatient therapies and rehabilitation for walking impaired persons with a relevant condition
Commercialization in Europe end-2018 and FDA in 2019
2018-2020 : Conducting clinical testings, to demonstrate medical benefits on patients with partial or complete SCI, severe neuromuscular diseases, post-stroke hemiparesis, and a fraction of patients with MS, CP, Parkinson related gait disorders.

Personal version:

Development and regulatory approval of the exo’s Personal version to deliver outpatient autonomy in daily life.
In a later stage, application to elderly will be developed.

Marketing perspectives

Rehabilitation center exo: Wandercraft is currently developing a clinical, commercial and support team to directly address the needs of rehabilitation centers and neurology hospitals in Europe. The team is planned to expand to North America in 2019 and Asia in 2020. The company anticipates to set a pricing model that will offer acquisition, leasing and subscription schemes, to adapt to various healthcare center needs.

Mehr Weniger


Anzahl der Beschäftigten





Physiotherapie / Orthopädietechnik